Severity of SARS-COV-2 infection and angiotensin converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis by Oscanoa, Teodoro J. et al.
106 www.ah.viamedica.pl
original paper
Address for correspondence: Teodoro J. Oscanoa, Universidad de San Martín de Porres, Facultad de Medicina Humana, 
Centro de Investigación de Seguridad de Medicamentos, Alameda del Corregidor 1531, La Molina 15024, Lima, Perú,
Hospital Almenara ESSALUD, Lima, Perú; Universidad Nacional Mayor de San Marcos, Facultad de Medicina, Lima, Perú
tel: (+511) 942 820820; e-mail: tjoscanoae@gmail.com; toscanoae@usmp.pe
Copyright © 2020 Via Medica, ISSN 2449–6170
Severity of SARS-COV-2 infection 
and angiotensin converting enzyme inhibitors 
and angiotensin receptor blockers:  
a meta-analysis
Teodoro J. Oscanoa 1, Xavier Vidal 2, Alfonso Carvajal 3, José Amado 1, 
Roman Romero-Ortuno 4
1Facultad de Medicina, Universidad Nacional Mayor de San Marcos, Drug Safety Research Centre, Facultad de Medicina Humana, 
Universidad de San Martín de Porres, Hospital Almenara, ESSALUD, Lima, Perú 
2Clinical Pharmacology Department, Vall d’Hebron Hospital, Barcelona, Spain
3Centro de Estudios sobre la Seguridad de los Medicamentos (CESME), Universidad de Valladolid, Valladolid, Spain
4Discipline of Medical Gerontology, Mercer’s Institute for Successful Ageing, St James’s Hospital, Dublin, Ireland; Global Brain Health Institute, 
Trinity College Dublin, Ireland
Abstract
Background: The mechanism of entry of SARS-CoV-2 into the human host cell is through the ACE2 receptor. 
During the pandemic, a hypothesis has been proposed that angiotensin-converting enzyme inhibitors (ACEIs) and 
angiotensin II receptor blockers (ARBs) could be risk factors for the development of severe SARS-CoV-2 infection. 
The objective of the study was to conduct a meta-analysis of the association between ACEI or ARB use and SARS-
CoV-2 infection severity or mortality.
Material and methods: We searched PubMed, EMBASE, Google scholar and the Cochrane Database of Systematic 
Reviews for observational studies published between December 2019 and August 4, 2020
Studies were included if they contained data on ACEI or ARB use and SARS-CoV-2 infection severity or mortal-
ity. Effect statistics were pooled using random-effects models. The quality of included studies was assessed with the 
Newcastle–Ottawa Scale (NOS). 
Data on study design, study location, year of publication, number of participants, sex, age at baseline, outcome 
definition, exposure definition, effect estimates and 95% CIs were extracted.
Results: Twenty-six studies (21 cohort studies and 5 case-control studies) were identified for inclusion, combining 
to a total sample of 361467 participants. Mean age was 61.48 (SD 8.26) years and 51.63% were men. The mean 
NOS score of included studies was 7.85 (range: 7–9). Results suggested that ACEI or ARB use did not increase the 
risk of severe disease or mortality from SARS-CoV-2 infection (OR = 0.88, 95% CI: 0.75–1.02, p > 0.05).
Conclusions: At present, the evidence available does not support the hypothesis of increased SARS-CoV-2 risk with 
ACEI or ARB drugs. 
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Introduction
It had not been anticipated that a phenomenon such 
as the appearance of the new SARS-CoV-2 pandemic 
would affect the world in such a short time and lead 
to serious health and economic consequences. Sci-
entists around the world are in a race against time in 
the search for effective treatment approaches. Among 
the many questions that need urgent clarification 
is that of the possible drug-disease interactions in 
patients taking angiotensin-converting enzyme in-
hibitors (ACEIs) and angiotensin II receptor block-
ers (ARBs). These are among the most widely used 
antihypertensive drug classes in the world [1].
The renin–angiotensin system (RAS) has the func-
tion of maintaining homeostasis of blood pressure, 
fluid and salt in the human body. The renin–angi-
otensin system contains two homologous enzymes 
belonging to the angiotensin converting enzyme 
(ACE) dipeptidyl carboxypeptidase family, with dif-
ferent functions: the angiotensin I converting enzyme 
1 (ACE1) converts angiotensin I to angiotensin II; 
and the angiotensin I converting enzyme 2 (ACE2) 
decreases the level of angiotensin II and negatively 
regulates the RAS system. Thus, ACE2 reduces the 
effects of vasoconstriction, sodium retention and fi-
brosis. ACE2 is expressed in various organs such as 
the heart, kidneys and especially in alveolar epithelial 
cells of the lung [2]. Under normal conditions, circu-
lating levels of soluble ACE2 are low and its function 
at the lung level is minimal [3]. 
The mechanism of entry of SARS-CoV-2 into 
the human host cell is through the ACE2 receptor. 
SARS-CoV-2 has an envelope made up of glycopro-
teins, called S1 (Spike) and S2, the former binding 
to ACE2 on the cell surface and the latter with 
the cell membrane [4]. While this mechanism is 
similar to that of another coronavirus that caused the 
SARS epidemic in 2002–2003 [5, 6], SARS-CoV-2 
has a higher affinity for ACE2 [7]. Although their 
three-dimensional structure is similar, SARS-CoV 
and SARS-CoV-2 differ in about 28% of the ami-
no acid sequence in the receptor binding domains; 
SARS-CoV-2 has a distinct loop with flexible glycyl 
residues replacing rigid prolyl residues, which makes 
its structure less rigid and may explain its greater af-
finity for the ACE2 receptor [7]. Angiotensin I con-
verting enzyme 2 was involved in the pathophysiol-
ogy of SARS-CoV infection [8] and it is feared that 
in SARS-CoV-2 infection, this effect could be of 
greater magnitude. In addition, prior to the pan-
demic it had been reported that ACEIs/ARBs could 
increase mRNA expression of ACE2 at the cardiac 
level [9]. Hence, it has been hypothesized that ACEIs 
and/or ARBs could be risk factors for the devel-
opment of severe forms of SARS-CoV-2 infection 
[10, 11]. In the midst of the COVID-19 pandemic 
crisis, this simple hypothesis was, without clinical or 
research evidence to support it, widely disseminated 
by the media, which in turn caused great concern to 
patients who were taking these medications. Offi-
cial statements rapidly followed recommending that 
these medications continue to be taken [12] in view 
of the absence of evidence to support the hypothesis. 
However, the absence of evidence does not mean 
evidence of absence and there is still an urgent need 
for clarification. In that light, we conducted a meta-
analysis of the association between ACEI or ARB 
use and SARS-CoV-2 infection severity or mortality.
Material and methods
This study was conducted following the guidelines of 
the Preferred Reporting Items for Systematic Reviews 
and Meta-analyses (PRISMA) [13].
Search strategy
Two independent investigators performed a system-
atic search in PubMed, EMBASE, Google scholar 
and the Cochrane Database of Systematic Reviews 
for observational studies published between Decem-
ber 2019 and August 4, 2020. In addition, we con-
ducted a secondary search based on the reference list 
of retrieved articles. The PubMed search strategy is 
detailed in Supplementary Table A. 
Eligibility criteria
We searched for randomized controlled trials (RCTs) 
or observational studies reporting data on ACEI or 
ARB use and SARS-CoV-2 infection severity or 
mortality. We included studies in English or other 
languages (all ages) meeting the following criteria: a) 
COVID-19 patients were diagnosed according to the 
interim guidance of the World Health Organization 
[14]; b) the study presented data on hazard ratios 
(HRs), relative risks (RRs), or odds ratios (ORs) with 
confidence intervals (CIs) or offered enough data 
to allow these to be calculated (including via email 
correspondence with original authors if necessary); 
and c) SARS-CoV-2 infection severity criteria were 
described. 
Quality assessment
The quality of observational studies (cohort and 
case-control studies) and RCTs were assessed accord-
ing to the Newcastle-Ottawa Quality Assessment 
Scale (NOS) [15] and the Cochrane Risk of Bias 
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Assessment Tool [16], respectively. Two investigators 
evaluated the quality of the studies independently. 
Conflicting results were resolved by discussion and 
involvement of a third reviewer if necessary.
Data extraction
The following data were extracted from each study: 
authors, study location, year of publication, study 
design, number of participants, sex, age at baseline, 
outcome definition, exposure definition, effect esti-
mates and 95% CIs. 
Statistical analyses
Primary analyses evaluated the association (HRs, 
RRs or ORs) between use of ACEI or ARB and 
SARS-CoV-2 infection severity or mortality. We 
used random effects with an inverse variance method 
to calculate the pooled RRs and 95% CIs accord-
ing to the heterogeneity between studies [17]. The 
overall estimates in the pooled analysis were obtained 
using Meta XL (www.epigear.com) add-in for Micro-
soft Excel.
Results
After screening 3781 citations, 26 studies (21 cohort 
studies and 5 case-control studies) were included 
(Fig. 1) [18–44], combining to a total sample of 
361467participants. The characteristics of included 
studies are summarized in Table 1. Thirteen studies 
were from China, 8 from USA and the other five 
being from Belgium, Italy, South Korea, Turkey and 
UK. Overall, mean age was 61.5 (SD 8.3) years and 
51.6% were men. The mean NOS score of included 
studies was 7.9 (range: 7–9). The outcomes reported 
in the included studies are presented in Table 1. 
For the meta-analysis, we used the combined out-
come of severe disease and/or mortality. As shown in 
Figure 2, the meta-analysis suggested that ACEI or 
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Table 1. Characteristics of the 26 studies included in the meta-analysis











Guo T. et al. 
(2020) China Cohort 186 58.5 48.7 Mortality ACEI/ARB 8
Hypertension (33%)  
Coronary heart disease (11%)
Cardiomyopathy (4%)
Diabetes mellitus (15%) 
COPD (2%)
Malignant neoplasm (7%)
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Feng Y. et al. 
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et al. (2020) China Cohort 274 60 45 Mortality ACEI/ARB 8
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COPD (6%)
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Cardiovascular disease (11%)
Diabetes mellitus (15%)  
Cerebrovascular disease (8%)
Zhang P. 
et al. (2020) China Cohort 1128 64 53.2 Mortality ACEI/ARB 7
Hypertension (100%)
Diabetes mellitus (23%)
Coronary heart disease (15%)
Chronic renal diseases (4%)
Cerebrovascular diseases (3%)
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Huang Z. 
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Ip A. et al. 
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Dublin S. 
et al. (2020) USA Cohort 322044 51 46
Severe 
disease ACEI/ARB 7
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Cancer (16%)
Chronic obstructive pulmonary 
disease (11%)
Lam K. el al. 








Chronic kidney disease (16%)
Senkal N. 







Coronary artery disease history (26%)
Congestive heart failure (9%)
ACEI — angiotensin-converting enzyme inhibitor; ARB — angiotensin II receptor blocker; SD — standard deviation; CI — confidence interval; RAS — renin–angiotensin system; NOS — Newcastle-Ottawa Scale;  
CC — case control; COPD — chronic obstructive pulmonary disease
Figure 2. Forest plot of the meta-analysis of the association between angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II recep-
tor blocker (ARB) use and SARS-CoV-2 infection severity or mortality. Analysis model: random effect. OR — odds ratio; CI — confidence 
interval
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ARB use did not increase the risk of severe disease or 
mortality from SARS-CoV-2 infection (OR = 0.88, 
95% CI: 0.75–1.02, p > 0.05). Subgroup analyses 
were conducted to assess ACEI and ARB effects sepa-
rately (Tab. 2) but no significant associations were 
found. Subgroup analyses were also negative for the 
effects of age (< 60 vs. 60+) or sex (Tab. 2).  
Discussion
Our study found no evidence to support the hy-
pothesis of increased SARS-CoV-2 risk with ACEI 
or ARB drugs. This would seem at odds with a pre-
vious finding that chronic use of ACEIs and ARBs 
was high among intensive care unit patients with 
non-COVID-19 sepsis [45]. However, it is possible 
that ACEIs/ARBs could be a marker of underly-
ing comorbidities rather than being causal in SARS- 
-CoV-2 severity or mortality.
Prior to the SARS-CoV-2 pandemic, Shinohara 
et al. published a meta-analytic study where they 
found a decreased risk of post-stroke pneumonia in 
patients treated with ACEIs compared to other anti-
hypertensive drugs (RR: 0.61, 95% CI: 0.51–0.75; 
p < 0.001) [46]. In another meta-analysis, Liu et al. 
found that ARBs were associated with a decreased 
risk of pneumonia morbidity (OR = 0.55, 95% CI: 
0.43–0.70, p < 0.01) and mortality (OR = 0.55, 
95% CI: 0.44–0.69, p < 0.01) [19]. These findings 
could however be seen from the perspective that the 
prescription of ACEIs/ARBs may be a marker of 
good general medical care, given the well-evidenced 
preventative role of these medications in many car-
diovascular and metabolic diseases. 
The basis for the hypothesis of a probable ACEI/ 
/ARB-induced increase in ACE2 expression has been 
recently revised, evaluating the results of 12 animal 
and 11 human studies [47]. In animal studies, no 
significant changes in ACE2 expression were found, 
and in those where it was evidenced, it was when 
models of acute injury were used or at higher doses 
than those used in humans; furthermore, no increase 
in ACE2 expression induced by ACEIs/ARBs was 
evidenced in human studies [47]. 
It has been proposed that ARBs may have pro-
tective effects on severity and mortality in SARS-
CoV-2 infection through increasing the production 
of angiotensin 1–7, reducing angiotensin II and 
contributing towards lung protection [48]. Re-
cently, Liu et al. found that angiotensin II levels 
in the plasma of COVID-19 infected patients was 
markedly elevated and linearly associated to viral 
load and lung injury [49]. However, this may be 
a marker of general physiological stress during se-
vere acute illness and not have specific drug-disease 
implications. 
Our study is limited in that it only relies on 
observational studies and not RCTs and includes 
a relatively small number of participants. It would 
be important that future, more powered studies, 
re-evaluate the possible relevance of age (young 
vs. old), sex, and possible different roles of ACEI 
and ARB drugs. It would also be important to as-
sess the risk of specific comorbidities (e.g. diabetes, 
hypertension, cerebrovascular disease, ischaemic 
heart disease) in the absence of ACEI/ARB drugs. 
For example, Feng et al. showed that hypertension 
without ACEI/ARB therapy was an independent 
risk factor for developing severe pneumonia irre-
spective of age [42].
In conclusion, the evidence available at present 
does not support the hypothesis of increased SARS-
CoV-2 risk with ACEI or ARB drugs. However, 
more evidence needs to accumulate before this con-
troversy can be resolved; in the meantime, clinicians 
may adopt a tailored, pragmatic approach that is sup-
ported by official recommendations [12, 50].
Table 2. Association between the use of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) 
and SARS-CoV-2 infection severity or mortality: summary of subgroup analyses
Subgroup Studies (n) Adjusted OR(95% CI) p
Mean age (years)
   < 60








   < 55







Type of RAS inhibitors
   ARB







RAS — renin–angiotensin system; OR — odds ratio; CI — confidence interval
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